Psoriasis
Conditions
Interventions
Secukinumab full dose administration group:During the induction period of week 0, 1, 2, 3, and 4, administer once every 300mg (2 injections) for a total of 10 injections
The instruction manual is recommended for patients weighing over 60kg. The maintenance period adopts a dosing method of once every 4 weeks, with 2 injections given each time until the skin lesions are
Secukinumab low dose administration group:During the induction period of week 0, 2, and 4, 300mg of medication was administered once each time, for a total of 6 injections. During the maintenance peri
Low dose combination of Secuknumab and apremilast group:During the induction period of week 0, week 2, and week 4, administer 300mg once each time for a total of 6 injections. During the maintenance p
Sponsors
Department of Dermatology, Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Psoriasis patients who regularly visit psoriasis specialist clinics for treatment; (2) Age 18-70 years old, both male and female are eligible; (3) Weight = 60kg; (4) Voluntarily accepting biologics targeting the IL-17 axis for treatment; (5) Qualified biological agent screening: no active tuberculosis, hepatitis B, AIDS, tumor, etc; (6) Moderate to severe psoriasis vulgaris (PASI score = 12 or BSA involvement = 10%), may be accompanied by joint damage (7) Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Prior to enrollment, have received treatment with other biologics and are within the 5 half lives of the biologics; (2) During screening, ALT or AST levels are greater than three times the upper limit of normal; (3) During the follow-up process, topical medications with therapeutic effects such as steroids, calcitriol, tacatine, and tazarotene were received, which affected the assessment of therapeutic efficacy; (4) During the follow-up process, other systemic treatments such as traditional Chinese medicine and phototherapy were combined; (5) Other types of psoriasis: erythrodermic psoriasis, pustular psoriasis (palmoplantar pustulosis and continuous acrodermatitis).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI 75; | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI 90;PASI 100; | — |
Countries
China
Contacts
Public Contactxu jinhua, han ling, Qin weiwei
Fudan University Affiliated Huashan Hospital
Outcome results
None listed